Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonates for advanced prostate cancer.

K K Yuen1, M Shelley, W M Sze

  • 1University of Hong Kong, Centre of Infection, Hong Kong, China. kyyuen@hkucc.hku.hk

The Cochrane Database of Systematic Reviews
|October 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postoperative stereotactic radiotherapy for brain metastases: results from a single-center retrospective analysis.

Clinical & experimental metastasis·2025
Same author

Trigeminal nerve injuries masquerading as erroneous facial palsy: a misunderstood presentation.

The British journal of oral & maxillofacial surgery·2023
Same author

Feasibility of virtual reality-delivered pain psychology therapy for cancer-related neuropathic pain: a pilot randomised controlled trial.

Anaesthesia·2023
Same author

Picture-in-picture video demonstration of systematic transperineal prostate biopsy.

Hong Kong medical journal = Xianggang yi xue za zhi·2021
Same author

A retrospective study on risk assessment and management of forensic psychiatric inpatients in Hong Kong.

Behavioral sciences & the law·2020
Same author

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Bisphosphonates may help relieve refractory bone pain and prevent skeletal events in men with metastatic prostate cancer. Further research is needed to optimize their use and guide treatment choices.

Area of Science:

  • Oncology
  • Pharmacology
  • Pain Management

Background:

  • Prostate cancer frequently metastasizes to bone, causing significant pain and complications.
  • Hormonal therapy is standard, but resistance develops, necessitating alternative treatments.
  • Bisphosphonates inhibit osteoclast activity and show promise for managing bone metastases.

Purpose of the Study:

  • To evaluate the effectiveness of bisphosphonates in alleviating bone pain for prostate cancer patients.
  • To assess the impact of bisphosphonates on skeletal events in metastatic prostate cancer.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials.
  • Inclusion of studies comparing bisphosphonates with placebo or open controls.
  • Extraction of data on pain response, skeletal events, and adverse events.

Related Experiment Videos

Main Results:

  • A trend towards improved pain relief was observed with bisphosphonates, though not statistically significant (OR 1.54, P=0.07).
  • Bisphosphonates significantly reduced skeletal events (OR 0.79, P=0.05).
  • Increased nausea was noted with bisphosphonates; no other adverse events significantly increased.

Conclusions:

  • Bisphosphonates are a viable option for refractory bone pain and skeletal event prevention in metastatic prostate cancer.
  • Further research is required to determine optimal bisphosphonate selection, dosage, and administration.
  • Standardization of pain assessment tools is crucial for future cancer pain research.